Breaking News
December 15, 2017 - Outcomes Poorer for Black Patients with Early Breast Ca
December 15, 2017 - Liposuction May Ease Limb Swelling in Cancer Patients
December 15, 2017 - How well can digital assistants answer questions on sex?
December 15, 2017 - NIH-funded study to explore hearing loss risk in Detroit firefighters
December 15, 2017 - Caris Life Sciences reveals identification of new mechanism of action to treat NHL
December 15, 2017 - Loyola Medicine study finds high success rate for diabetic Charcot foot surgery
December 15, 2017 - Bone marrow edema does not increase due to intense physical activity, study finds
December 15, 2017 - Human ‘common cold’ virus kills healthy chimpanzees in Uganda
December 15, 2017 - Experience of reflex walking refines perception of biological motion during early infancy
December 15, 2017 - FDA Approves Admelog (insulin lispro) Rapid-Acting “Follow-On” Insulin Product to Treat Diabetes
December 14, 2017 - Friday Feedback: Good Idea for Ex-Pharma Exec to Run HHS?
December 14, 2017 - More than 200 people sickened onboard Ovation of Seas cruise
December 14, 2017 - FDA announces new approach for sharing updates on antibiotics, antifungal drugs to physicians
December 14, 2017 - Steroid study provides new insights into medicines’ side effects
December 14, 2017 - Government announces plans to include eye test reminder during driving license renewal
December 14, 2017 - Non-ionizing radiation from magnetic fields could have adverse biological impacts on health
December 14, 2017 - Bi-annual MRI beats mammograms in detecting breast cancer among women with genetic risk
December 14, 2017 - Researchers develop new method for quickly detecting signs of multiple sclerosis
December 14, 2017 - In era of increased competition, hospitals fret over ratings
December 14, 2017 - Female veterans experience improvement in low back pain with course of chiropractic care
December 14, 2017 - Relieving Symptoms of Cystic Fibrosis with Exercise
December 14, 2017 - FDA Alert: Blue Pearl All Natural Male Enhancement Supplement: Recall
December 14, 2017 - CardioBrief: In Defense Of ORBITA
December 14, 2017 - Definition of High Blood Pressure Drops: MedlinePlus Health News
December 14, 2017 - Drug may help surgical patients stop opioids sooner
December 14, 2017 - Researchers develop biosensor that enables development of new health tests
December 14, 2017 - Radiation therapy can be used to treat patients with life-threatening heart rhythm
December 14, 2017 - UVA researchers developing tool to help prostate cancer patients weigh treatment options
December 14, 2017 - Experts tell Congress how to cut drug prices
December 14, 2017 - Researchers use cryptographic techniques to decode activity of motor neurons
December 14, 2017 - Study finds changes in the heart after spinal cord injury
December 14, 2017 - Health Highlights: Dec. 12, 2017
December 14, 2017 - Pelzman’s Picks: How States Can Cut Disparities in Care and Costs
December 14, 2017 - New Hemophilia Treatment Stems Bleeding Episodes: MedlinePlus Health News
December 14, 2017 - Onetime ‘world’s heaviest man’ has second surgery in Mexico
December 14, 2017 - Belgian researchers create transplantable artificial ovary prototype
December 14, 2017 - Using atraumatic needles for lumbar punctures decreases risk of complications
December 14, 2017 - Outpatient total knee replacement surgery linked to higher rates of complications
December 14, 2017 - Social impairments can be corrected by brain stimulation
December 14, 2017 - Studies reveal possibility for memory T cells to serve a dual purpose
December 14, 2017 - Antibody-Drug Conjugate Ups PFS in Untreated Hodgkin’s
December 14, 2017 - Study finds reading information aloud to yourself improves memory
December 14, 2017 - Researchers use RNA nanotechnology to program exosomes for delivering effective cancer therapies
December 14, 2017 - Living Lyme disease bacteria found months after antibiotic treatment
December 14, 2017 - These annual checkups help seniors not only survive but thrive
December 14, 2017 - Study reveals impact of diabetes during pregnancy on baby’s heart
December 14, 2017 - Hydraulic fracturing is harmful to infants health, study states
December 14, 2017 - Huntington’s disease drug clears initial hurdles
December 14, 2017 - TPU researchers create 3D-printed models of children’s hearts
December 14, 2017 - Brain responses of children with inherited dyslexia risk predict their future reading speed
December 14, 2017 - People diagnosed with schizophrenia or bipolar disorder may actually have treatable condition
December 14, 2017 - Study: New Furosemide Formulation Simplifies Administration for HF
December 14, 2017 - Discrimination harms your health—and your partner’s
December 14, 2017 - Having older brothers may increase the likelihood of being gay
December 14, 2017 - New scientific yardstick released to help early detection of Alzheimer’s disease
December 14, 2017 - New finding demonstrates what happens at cellular level during onset of type2 diabetes
December 14, 2017 - Study identifies potassium as key to circadian rhythms in red blood cells
December 14, 2017 - Good friends might be your best brain booster as you age
December 14, 2017 - NIH expected to award up to $70 million to launch Alzheimer’s Clinical Trials Consortium
December 14, 2017 - Pitting pathogens against each other could prevent drug resistance emerging
December 14, 2017 - Study provides new insights into development of Sonic Hedgehog medulloblastoma
December 14, 2017 - Dr. Reddy’s Announces Approval of Impoyz (clobetasol propionate) Cream for Plaque Psoriasis
December 14, 2017 - Gene Screens Can Alter Perception, Behavior
December 14, 2017 - Can Scrotal Vein Condition Hike Heart Risks?: MedlinePlus Health News
December 14, 2017 - Molecules in spit may be able to diagnose and predict length of concussions
December 14, 2017 - Children’s Colorado and RxRevu partner to help prescribers better meet needs of pediatric patients
December 14, 2017 - Researchers discover new way to attack drug-resistant prostate cancer cells
December 14, 2017 - Scientists develop new, high resolution method for identifying microbial species and strains
December 14, 2017 - Declining trend of salmonellosis cases has leveled off in the EU
December 14, 2017 - Death receptors in the blood can help measure risk of cardiovascular diseases, type 2 diabetes
December 14, 2017 - How to Perk Up the Holidays for Hospital Patients
December 14, 2017 - Prolonged Sedation May be Bad for Baby’s Brain
December 14, 2017 - The pediatric submersion score predicts children at low risk for injury following submersions
December 14, 2017 - Video game helps doctors to quickly recognize trauma patients who need high levels of care
December 14, 2017 - Younger persons newly-diagnosed with type 2 diabetes have poorer health than older patients
December 14, 2017 - Clinician re-examines evidence on re-use of catheters and UTIs in people with spinal cord injuries
December 14, 2017 - UK and Russian researchers join forces against AMR
December 14, 2017 - Results of Bariatric Surgery Hold Up Over Time
December 14, 2017 - High-intensity exercise delays Parkinson’s progression
December 14, 2017 - Protein structure could pave way for effective drugs to treat cystic fibrosis
PCSK9 inhibitor offers clinical benefit to patients with peripheral artery disease

PCSK9 inhibitor offers clinical benefit to patients with peripheral artery disease

image_pdfDownload PDFimage_print

Patients with peripheral artery disease (PAD) are at high risk of heart attack, stroke and cardiovascular death. In addition, PAD patients can suffer major adverse limb events, such as acute limb ischemia – the equivalent of a heart attack in the leg – that can lead to limb loss. Managing PAD is challenging for patients and physicians alike – despite best available treatment including high-intensity statins, risk of cardiovascular and limb events remains high. With few clinical trials focused on patients with PAD, physicians must often extrapolate from studies in broader populations with atherosclerosis about the best treatment approach for these patients. Unfortunately, few of these studies have characterized limb risk and fewer have demonstrated benefits of preventive therapies in reducing this risk. A new sub-analysis of the FOURIER clinical trial, however, now offers information on the safety and effectiveness of giving the PCSK9 inhibitor evolocumab on top of statin therapy to this high-risk population. At the 2017 American Heart Association Scientific Sessions, Marc Bonaca, MD, MPH, investigator at the TIMI Study Group and director of the Aortic Disease Center at Brigham and Women’s Hospital, presented results from the sub-analysis, which are published simultaneously in Circulation.

“Whenever trials like FOURIER demonstrate benefit of a therapy in a broad population, we then want to understand the efficacy and safety in subpopulations to help clinicians understand which patients are going to derive the greatest absolute benefit. We’ve found that several sub-groups of patients respond well to evolocumab, but it’s especially encouraging to see these results for patients with PAD since this is a population at heightened cardiovascular risk and there are few therapies that modify limb risk,” said Bonaca. “We see that adding evolocumab can make a big difference for these patients.”

The team analyzed data from more than 3,600 trial participants, half of whom had no history of a heart attack or stroke. Evolocumab reduced risk of a future cardiovascular event for patients with or without PAD. Because patients with PAD are at especially high risk of a heart attack or stroke, these patients had a higher absolute risk reduction (3.5% PAD, 1.6% no PAD) of a cardiovascular event. In addition, evolocumab reduced their risk of a major adverse limb event by about half, compared to PAD patients who received the placebo. Among patients with PAD and no history of a heart attack or stroke, evolocumab reduced risk of a cardiovascular or adverse limb event by 6 percent over 2.5 years. Researchers report that the number needed to treat (NNT) – that is, how many patients would need to be prescribed the drug for 2.5 years to prevent an adverse event – is as low as 16 for this patient population. The team found no offsetting safety concerns.

Bonaca will present PAD findings as part of a Clinical Trials Update at the Scientific Sessions. Several other AHA Scientific Sessions related to FOURIER will be presented by BWH investigators. These include a second Clinical Trials Update presented by Marc Sabatine, MD, analyzing the clinical benefit of evolocumab in different subgroups of patients with a history of heart attacks, finding that those who are at higher risk – including those closer to their most recent heart attack, with multiple prior heart attacks or with multivessel disease – also reap greater relative and absolute risk reduction from the treatment. BWH investigators will also present oral presentations on the efficacy of evolocumab on different types of myocardial infractions, such as STEMI. In addition, investigators will present on the efficacy of evolocumab in reducing total cardiovascular events. Most cardiovascular trials only take into account the first cardiovascular event a patient goes on to experience, but many patients who experience a non-fatal heart attack will experience additional events. Taking these later events into account, evolocumab prevented double the number of events, compared with first events only. Finally, investigators will also present a poster on the application of the TIMI Risk Score for stable ischemic heart disease to FOURIER.

“As we continue to analyze the FOURIER data, we gain greater insight into the patients who enjoy the most substantial clinical benefits from intensive LDL-C lowering with the PCSK9 inhibitor evolocumab,” said Sabatine.

Evolocumab is a member of a new class of cholesterol lowering drugs known as PCSK9 inhibitors that have emerged as an effective treatment for drastically lowering LDL cholesterol beyond what is possible with statin therapy alone. Previous research demonstrated that evolocumab effectively reduces LDL cholesterol by approximately 60 percent. The FOURIER trial (Further Cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk) was designed to determine whether evolocumab, when added to statin therapy, would reduce adverse cardiovascular events.

FOURIER was designed in a collaboration between the Executive Committee and the trial sponsor, Amgen, which manufactures evolocumab and provided a research grant to the TIMI Study Group at BWH. The TIMI Study Group conducted all data analyses presented in the paper. Sabatine and the TIMI Study Group receive research grants from various pharmaceutical companies that produce other lipid-lowering therapies and Sabatine reports receiving honoraria from Amgen and various pharmaceutical companies that produce other lipid-lowering therapies.

Source:

http://www.brighamandwomens.org/

Tagged with:

About author

Related Articles